01—Abstract
Summary
Summary of the 8-K filed December 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. (NYSE: HUM) announced on December 3, 2024 that Chief Financial Officer Susan M.
Diamond will transition from her role on January 10, 2025, to pursue personal and professional goals, and will serve in an advisory capacity through December 31, 2025. Under her agreement, she will continue to receive her current base salary, annual incentive opportunity and benefits through December 31, 2025, then move to the company's variable staffing pool as a temporary worker until March 1, 2027, paid only hourly for work performed. At the end of the transition period she is eligible for benefits under Section 3 of the Executive Severance Policy, subject to a general release and non-compete and non-solicit compliance.
The company stated her departure is not related to any disagreement with the company. Celeste Mellet, currently CFO of Global Infrastructure Partners, was appointed to succeed Diamond as Chief Financial Officer effective January 11, 2025. Her offer letter provides a base salary of $975,000,a a 125% short-term incentive target level, an initial restricted stock unit award of approximately $6,000,000, a 2025 annual equity grant of $4,000,000, and a cash sign-on payment totaling $7,300,000 in three installments, subject to repayment if she leaves voluntarily before certain service requirements are met.
The payments are intended to replace compensation she forfeited from her prior employment. In a Regulation FD disclosure, management stated it intends to reaffirm FY 2024 guidance of at least $12.89b diluted EPS or at least $16.00 Adjusted EPS during investor meetings between December 3 and December 31, 2024, consistent with the October 30, 2024 guidance. The release also reiterates 2025 adjusted EPS commentary of "at least in line with final 2024 results" and notes a targeted Investor Day in May 2025.
02—Key points
Key Highlights
- CFO Susan M. Diamond transitions out effective January 10, 2025, with an advisory role through December 31, 2025 and temporary worker status until March 1, 2027.
- Celeste Mellet, formerly CFO of Global Infrastructure Partners, appointed CFO effective January 11, 2025.
- Mellet's compensation includes a $975,000 base salary, 125% short-term incentive participation, roughly $6,000,000 initial RSU award, and a $4,000,000 2025 annual equity grant.
- Mellet receives a $7,300,000 cash sign-on payment in three installments of $6,000,000, $700,000 and $600,000, with clawback provisions if she leaves voluntarily early.
- Management intends to reaffirm FY 2024 guidance of at least $12.89 diluted EPS or at least $16.00 Adjusted EPS during investor meetings in December 2024.
- The reconciliation shows GAAP-to-Adjusted EPS adjustments including amortization of intangibles ($0.50), put/call valuation adjustments ($1.17), exit of employer group commercial medical products ($1.14), and value creation initiatives ($1.25).
- Company reiterates 2025 adjusted EPS commentary of at least in line with final 2024 results and targets an Investor Day in May 2025.
03—Questions
Frequently Asked Questions
Why is Susan Diamond leaving the CFO role?
The filing states she is transitioning to pursue personal and professional goals. The company said her departure is not related to any disagreement with Humana, including regarding its operations, policies or practices.
Who is replacing Susan Diamond as CFO, and when does the change take effect?
Celeste Mellet, currently CFO of Global Infrastructure Partners, will become CFO effective January 11, 2025. Diamond's transition date is January 10, 2025.
What compensation will Celeste Mellet receive?
Her offer letter provides a $975,000 base salary, eligibility for the 125% level of the short-term incentive plan, an initial RSU award of approximately $6,000,000, a 2025 annual equity grant of $4,000,000, and a cash sign-on payment of $7,300,000 payable in installments.
What happens to Susan Diamond's compensation after she steps down?
Through December 31, 2025, she will keep her current base salary, annual incentive opportunity and benefits. During the variable staffing pool period through March 1, 2027, she will receive no salary, only an hourly rate for work performed, and will continue equity vesting under the stock incentive plan.
What did Humana say about its 2024 earnings guidance?
Management intends to reaffirm FY 2024 guidance of at least $12.89 diluted EPS or at least $16.00 Adjusted EPS during investor meetings through December 31, 2024, consistent with its October 30, 2024 guidance.
04—Continue